MapLight Therapeutics (MPLT) EBITDA (2024 - 2025)
MapLight Therapeutics recorded quarterly EBITDA of -$79.8 million in Q4 2025, down 171.3% quarter-over-quarter from -$29.4 million in Q3 2025, and down 271.37% year-over-year from $46.6 million in Q4 2024.
MapLight Therapeutics' EBITDA history runs 2 years deep, the most recent figure standing at -$79.8 million for Q4 2025.
- In Q4 2025, EBITDA fell 271.37% year-over-year to -$79.8 million; the TTM figure through Dec 2025 stood at -$149.1 million (changed N/A YoY), while the FY2025 annual figure was -$161.5 million, down 108.67% from the prior year.
- EBITDA came in at -$79.8 million for Q4 2025 at MapLight Therapeutics, down from -$29.4 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$18.4 million in Q3 2024 to a low of -$79.8 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 201.19 Mn |
| 10 | MapLight Therapeutics | 254.43 Mn | 254.43 Mn | - | -79.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -79.82 Mn |
| Sep 30, 2025 | -29.42 Mn |
| Dec 31, 2024 | -21.49 Mn |
| Sep 30, 2024 | -18.40 Mn |